 |
|
RNA interference as a novel treatment strategy for chronic hepatitis B infection
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2022;28(3):408-424. Published online 2022 Feb 17 DOI: https://doi.org/10.3350/cmh.2022.0012
|
|
Citations to this article as recorded by
 Recent Progress in Phage‐Based Nanoplatforms for Tumor Therapy
Xiao‐Tong Li, Shu‐Yi Peng, Shao‐Mei Feng, Ting‐Yu Bao, Sheng‐Zhang Li, Shi‐Ying Li
Small.2024;[Epub] CrossRef Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics
Jie-Li Hu, Ai-Long Huang
Virologica Sinica.2024; 39(1): 9. CrossRef Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo
Elena M. Smekalova, Maria G. Martinez, Emmanuel Combe, Anuj Kumar, Selam Dejene, Dominique Leboeuf, Chao-Ying Chen, J. Robert Dorkin, Lan Shuan Shuang, Sarah Kieft, Lauren Young, Luis Alberto Barrera, Michael S. Packer, Giuseppe Ciaramella, Barbara Teston
Molecular Therapy - Nucleic Acids.2024; 35(1): 102112. CrossRef Can Radionuclide Therapy be the Solution for Hepatitis B Virus Infection?
Pil Soo Sung, Ie Ryung Yoo
Nuclear Medicine and Molecular Imaging.2024; 58(5): 255. CrossRef RNA nanomedicine in liver diseases
Anita Bakrania, Yulin Mo, Gang Zheng, Mamatha Bhat
Hepatology.2024;[Epub] CrossRef Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161
Angela M. Lam, Ravi R. Dugyala, Muhammed Sheraz, Fei Liu, Emily P. Thi, Ingrid E. Graves, Andrea Cuconati, Holly Micolochick Steuer, Andrzej Ardzinski, Nathan Overholt, Jeremy D. Mason, Dimitar Gotchev, Andrew G. Cole, Troy O. Harasym, Michael J. Sofia
Viruses.2024; 16(3): 323. CrossRef Retreatment with HBV siRNA Results in Additional Reduction in HBV Antigenemia and Immune Stimulation in the AAV-HBV Mouse Model
Ellen Van Gulck, Nádia Conceição-Neto, Liese Aerts, Wim Pierson, Lore Verschueren, Mara Vleeschouwer, Vinod Krishna, Isabel Nájera, Frederik Pauwels
Viruses.2024; 16(3): 347. CrossRef Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies
Hui Ma, Qing-Zhu Yan, Jing-Ru Ma, Dong-Fu Li, Jun-Ling Yang
World Journal of Gastroenterology.2024; 30(10): 1295. CrossRef Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873
Darryl Kato, Regina Wai-Yan Choy, Eda Canales, Ryan A. Dick, April D. Lake, Nathan D. Shapiro, Elbert Chin, Jiayao Li, Jennifer R. Zhang, Qiaoyin Wu, Roland D. Saito, Sammy Metobo, Evangelos Aktoudianakis, Scott D. Schroeder, Zheng-Yu Yang, Dylan M. Glatt
ACS Medicinal Chemistry Letters.2024; 15(4): 546. CrossRef Model‐based meta‐analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B‐infected mice
Louis Sandra, Huybrecht T'jollyn, An Vermeulen, Oliver Ackaert, Juan‐Jose Perez‐Ruixo
CPT: Pharmacometrics & Systems Pharmacology.2024; 13(5): 729. CrossRef Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents
Robert Lam, Joseph K Lim
World Journal of Hepatology.2024; 16(3): 331. CrossRef Prospects for Controlling Hepatitis B Globally
Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Fernando de Jesús, Octavio Corral, Carmen de Mendoza
Pathogens.2024; 13(4): 291. CrossRef Therapeutic advances in HBV cure
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clinical Liver Disease.2024;[Epub] CrossRef Genotyping Hepatitis B virus by Next-Generation Sequencing: Detection of Mixed Infections and Analysis of Sequence Conservation
Eva Dopico, Marta Vila, David Tabernero, Josep Gregori, Ariadna Rando-Segura, Beatriz Pacín-Ruíz, Laura Guerrero, Itziar Ubillos, Miguel J. Martínez, Josep Costa, Josep Quer, Javier Pérez-Garreta, Alejandra González-Sánchez, Andrés Antón, Tomás Pumarola,
International Journal of Molecular Sciences.2024; 25(10): 5481. CrossRef Analysis of the pharmacokinetics and efficacy of RBD1016 – A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK/PD model
Qian Li, Taohua Geng, Haiyan Li, Shuquan Zheng, Sara Svedlund, Liming Gan, Ann-Charlotte Egnell, Shan Gao, Rui Chen, Pei Hu
Heliyon.2024; 10(11): e31924. CrossRef Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection
Wenjing Zai, Min Yang, Kuan Jiang, Juan Guan, Huijing Wang, Kongying Hu, Chao Huang, Jieliang Chen, Wei Fu, Changyou Zhan, Zhenghong Yuan
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef Discovery of hepatitis B virus subviral particle biogenesis inhibitors from a bioactive compound library
Biplav Shrestha, Sisi Yang, Lauren Griffith, Julia Ma, Fuxuan Wang, Hui Liu, Qiong Zhao, Yanming Du, Jiming Zhang, Jinhong Chang, Ju-Tao Guo
Antiviral Research.2024; 228: 105955. CrossRef Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim
Clinical and Molecular Hepatology.2024; 30(3): 539. CrossRef Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain
Lanlan Liu, Haoyu Wang, Lulu Liu, Fang Cheng, Haji Akber Aisa, Changfei Li, Songdong Meng
Viruses.2024; 16(7): 1151. CrossRef The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy
Mingming Zhang, Han Chen, Huan Liu, Hong Tang
Biomarker Research.2024;[Epub] CrossRef Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989
Lung Yi Mak, Christine I Wooddell, Oliver Lenz, Thomas Schluep, James Hamilton, Heather L Davis, Xianhua Mao, Wai-Kay Seto, Michael Biermer, Man-Fung Yuen
Gut.2024; : gutjnl-2024-333026. CrossRef Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants
Haiyan Li, Xiaoye Niu, Yu Zhang, Danning Zhang, Yanqing Zhang, Liqun Wang, Yongqing Miao, Yanxin Jiang, Jia Ji, Qiaoqiao Chen, Xiaoyun Wu, Emmanuel Njumbe Ediage, Thomas N. Kakuda, Michael Biermer
Clinical Pharmacology in Drug Development.2023; 12(2): 175. CrossRef Therapies against chronic hepatitis B infections: The times they are a-changin’, but the changing is slow!
David Durantel
Antiviral Research.2023; 210: 105515. CrossRef New Approaches to Chronic Hepatitis B
Dan L. Longo, Geoffrey Dusheiko, Kosh Agarwal, Mala K. Maini
New England Journal of Medicine.2023; 388(1): 55. CrossRef The scientific basis of combination therapy for chronic hepatitis B functional cure
Seng Gee Lim, Thomas F. Baumert, Carolina Boni, Ed Gane, Massimo Levrero, Anna S. Lok, Mala K. Maini, Norah A. Terrault, Fabien Zoulim
Nature Reviews Gastroenterology & Hepatology.2023; 20(4): 238. CrossRef Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review
Jie-Li Hu, Ai-Long Huang
Microorganisms.2023; 11(3): 600. CrossRef Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation
Sihui Zhang, Chao Wang, Bei Liu, Qing-Bin Lu, Jia Shang, Yihua Zhou, Jidong Jia, Xiaoyuan Xu, Huiying Rao, Bingfeng Han, Tianshuo Zhao, Linyi Chen, Mingzhu Xie, Jiahao Cui, Juan Du, Jing zeng, Ninghua huang, Yaqiong Liu, Lei Zhang, Hui Zhuang, Fuqiang Cui
The Lancet Regional Health - Western Pacific.2023; 35: 100738. CrossRef The progress of molecules and strategies for the treatment of HBV infection
Youlu Pan, Heye Xia, Yanwen He, Shenxin Zeng, Zhengrong Shen, Wenhai Huang
Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen, James Fung
Expert Review of Gastroenterology & Hepatology.2023; 17(5): 443. CrossRef Current and novel modalities for management of chronic hepatitis B infection
Iman Ibrahim Salama, Samia M Sami, Somaia I Salama, Ghada A Abdel-Latif, Fatma A Shaaban, Walaa A Fouad, Aida M Abdelmohsen, Hala M Raslan
World Journal of Hepatology.2023; 15(5): 585. CrossRef Past, present, and future of long-term treatment for hepatitis B virus
Teresa Broquetas, José A Carrión
World Journal of Gastroenterology.2023; 29(25): 3964. CrossRef Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers
Lung-Yi Mak, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen
Clinics in Liver Disease.2023; 27(4): 877. CrossRef RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease
Pavel Strnad, Javier San Martin
Expert Opinion on Investigational Drugs.2023; 32(7): 571. CrossRef Chronic Hepatitis B Infection: New Approaches towards Cure
Mojisola Ogunnaike, Srijanee Das, Samiksha S. Raut, Ashrafi Sultana, Mohammad Ullah Nayan, Murali Ganesan, Benson J. Edagwa, Natalia A. Osna, Larisa Y. Poluektova
Biomolecules.2023; 13(8): 1208. CrossRef Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen
Expert Opinion on Investigational Drugs.2023; 32(11): 971. CrossRef Cell-Penetrating Peptides as Vehicles for Delivery of Therapeutic Nucleic Acids. Mechanisms and Application in Medicine
Ekaterina D. Timotievich, Igor P. Shilovskiy, Musa R. Khaitov
Biochemistry (Moscow).2023; 88(11): 1800. CrossRef Gene-Editing and RNA Interference in Treating Hepatitis B: A Review
Nadiia Kasianchuk, Krystyna Dobrowolska, Sofiia Harkava, Andreea Bretcan, Dorota Zarębska-Michaluk, Jerzy Jaroszewicz, Robert Flisiak, Piotr Rzymski
Viruses.2023; 15(12): 2395. CrossRef Peptide carriers as delivery vehicles for therapeutic nucleic acids. Мechanisms and potential applications in medicine
E. D Timotievich, I. P Shilovskiy, M. R Khaitov
Биохимия.2023; 88(11): 2183. CrossRef KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials
Rex Wan-Hin Hui, Lung Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Expert Opinion on Emerging Drugs.2022; 27(2): 127. CrossRef Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection
Ilaria Montali, Andrea Vecchi, Marzia Rossi, Camilla Tiezzi, Amalia Penna, Valentina Reverberi, Diletta Laccabue, Gabriele Missale, Carolina Boni, Paola Fisicaro
Biomedicines.2022; 10(6): 1224. CrossRef Hepatitis B x (HBx) as a Component of a Functional Cure for Chronic Hepatitis B
Mark A. Feitelson, Alla Arzumanyan, Ira Spector, Arvin Medhat
Biomedicines.2022; 10(9): 2210. CrossRef Novel Combination Strategies With Investigational Agents for Functional Cure of Chronic Hepatitis B Infection
Rex Wan-Hin Hui, Lung-Yi Mak, Ka-Shing Cheung, James Fung, Wai-Kay Seto, Man-Fung Yuen
Current Hepatology Reports.2022; 21(4): 59. CrossRef State-of-the-art and emerging antivirals for chronic hepatitis B infection
Margarita Papatheodoridi, George V. Papatheodoridis
Expert Opinion on Pharmacotherapy.2022; 23(18): 1999. CrossRef
|